Here are 1-3 brief analogies for Natera (NTRA):

• Like a specialized Quest Diagnostics, focusing on advanced genetic and molecular tests for conditions like prenatal disorders and cancer.
• Think Guardant Health for genetic cancer monitoring, but also a leader in genetic tests for prenatal health and organ transplant management.

• Panorama: A non-invasive prenatal test screening for fetal chromosomal abnormalities and twin zygosity.
• Vistara: A single-gene mutation screening test to identify single-gene disorders.
• Horizon carrier screening: A test to determine an individual's carrier status for various genetic diseases.
• Spectrum: A test used during in vitro fertilization cycles to identify chromosomal anomalies or inherited genetic conditions.
• Anora miscarriage test: A product analyzing fetal chromosomes to determine the cause of miscarriage.
• Non-invasive paternity testing: A service to determine paternity during gestation using blood draws from the mother and alleged father.
• Constellation: A cloud-based software product providing laboratory customers access to Natera's algorithms and bioinformatics for test validation and launch.
• Signatera: A circulating tumor DNA technology used to screen for a generic set of mutations independent of an individual's tumor.
• Prospera: A test used to assess organ transplant rejection.

Natera (NTRA) primarily sells its products and services to other companies, rather than directly to individuals. Its major customer categories and specific company partners are:

• Laboratories: Natera provides its Constellation cloud-based software product, which enables laboratory customers to access its algorithms and bioinformatics to validate and launch tests. Furthermore, Natera offers its molecular testing services through a network that includes approximately 100 laboratory partners worldwide.
• Distribution Partners: The company utilizes a network of approximately 100 distribution partners to commercialize its products, indicating these partners purchase and distribute Natera's offerings.
• BGI Genomics Co., Ltd. (300676.SZ): Natera has a partnership agreement with BGI Genomics to develop, manufacture, and commercialize NGS-based genetic testing assays.
• Foundation Medicine, Inc.: Natera has a partnership agreement with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays. Foundation Medicine was formerly a public company (symbol FMI) but is now a subsidiary of Roche Holding AG.

• BGI Genomics Co., Ltd. (SZSE: 300676)
• Foundation Medicine, Inc.

Steve Chapman joined Natera in 2010 and has served as Chief Executive Officer since January 2019, also serving on the company's board of directors. Before becoming CEO, he held several other leadership positions at Natera, including Chief Operating Officer, Chief Commercial Officer, Senior Vice President of Commercial, and Vice President of Sales. He notably led Natera's commercial entry into the non-invasive prenatal testing market, where its Panorama® test became a market leader. Prior to Natera, Chapman worked at Genzyme Genetics, where he was recognized for achieving record-breaking commercial growth and implementing strategies that transformed pregnancy genetic testing. He began his career as a researcher in the department of human genetics at the University of California, Los Angeles (UCLA), focusing on identifying SNPs associated with multiple sclerosis. Chapman holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA. He was named a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year.

Michael Brophy has served as Natera's Chief Financial Officer since February 2017, having joined the company in 2015. During his tenure at Natera, he held roles as Vice President of Corporate Development and Investor Relations and Senior Vice President of Finance and Investor Relations. Before joining Natera, Brophy worked in the investment banking division of Morgan Stanley as a Vice President and Executive Director, where he specialized in advising corporate clients within the life science tools and diagnostics sector. He earned an MBA from the University of California, Los Angeles, and a Bachelor of Science degree in Economics from the United States Air Force Academy.

Solomon Moshkevich joined Natera in 2011 and currently serves as President of Clinical Diagnostics, overseeing productization, clinical validation, commercialization, and quality across the company. He has been instrumental in building and leading various teams, including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management, and portfolio strategy. Moshkevich played a key role in the development, clinical validation, and commercial success of all of Natera's cell-free DNA products, such as Panorama, Prospera, and Signatera. He previously served as General Manager of Oncology. Moshkevich began his career as a consultant with Bain & Company and later joined the private equity investment team at Parthenon Capital. He holds an MBA from Stanford University and a B.A. in economics and mathematics from Columbia University.

Matthew Rabinowitz is a co-founder of Natera, Inc., which was initially known as Gene Security Network, Inc. He currently serves as the Executive Chairman of its board of directors. From 2005 to 2019, Rabinowitz held the position of Natera's Chief Executive Officer. He manages an early-stage technology venture fund that focuses on biotech, security, and artificial intelligence (AI). Additionally, Rabinowitz serves as a chairman, director, and/or advisor for numerous companies and nonprofits involved in diagnostics, biotech, AI, health services, and nature conservation.

John Fesko joined Natera in 2014 and was promoted to President & Chief Business Officer in September 2023. He oversees reimbursement strategy and market access, patient operations and experience, marketing and communications, government affairs, business and market development, pharmaceutical services, and international commercial operations. Fesko previously held various leadership roles of increasing responsibility at Natera, including Chief Business Officer since 2019. Prior to his time at Natera, he gained experience working at Roche, Novartis Pharma AG, MPM Capital, and InVivoScribe.

Reimbursement and Regulatory Challenges

Intense Competition and Rapid Technological Obsolescence

Intellectual Property Litigation and Protection

Here are 3-5 expected drivers of future revenue growth for Natera (NTRA) over the next 2-3 years:

1. Continued strong growth of Signatera (Oncology Segment): Natera's Signatera molecular residual disease (MRD) test is consistently highlighted as a key revenue driver. The company has reported substantial year-over-year increases in oncology test volumes, with a 56% rise in MRD clinical units in Q4 2025 compared to Q4 2024, and 55% growth in oncology tests in Q4 2024 over Q4 2023. Analysts and management anticipate continued robust sequential growth for Signatera. Growth is further supported by expanding reimbursement coverage across various cancer types, guideline updates for circulating tumor DNA (ctDNA), and the launch of new products like the Latitude Tissue-Free MRD test.
2. Expansion of Prospera (Organ Health Segment): The Prospera test, used to assess organ transplant rejection, is another significant growth area. Natera expects strong sequential growth from Prospera. The organ health segment experienced nearly 50% year-on-year volume growth in Q4 2024, and the company has launched new features, such as those for Prospera Heart, to enhance rejection detection in heart transplant patients.
3. Increase in overall test volumes and average selling prices (ASPs) across the product portfolio: Natera has consistently demonstrated growth driven by both increased test volumes and improvements in average selling prices across its range of services. In Q4 2024, revenues grew almost twice as fast as volumes, attributed to improving ASPs for products including Panorama (non-invasive prenatal test) and Horizon (carrier screening). Strategic efforts to secure reimbursement for covered services are also contributing to these ASP improvements.
4. Launch of new products, expanded indications, and pipeline catalysts: Natera's commitment to innovation and its robust pipeline are expected to fuel future revenue. Recent examples include the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test (NIPT). The company also anticipates future growth from upcoming clinical readouts in oncology, kidney/heart transplantation, and fetal RhD NIPT, as well as potential guideline updates and international approvals.

Share Issuance

• In September 2023, Natera completed an underwritten equity offering, raising approximately $235.8 million net of underwriting discounts.
• The company redeemed all of its outstanding 2.25% Convertible Senior Notes due 2027, converting $287.4 million of notes into approximately 7.5 million shares of common stock.
• Weighted-average shares outstanding increased from 124.7 million in 2024 to 136.7 million in 2025.

Outbound Investments

• In December 2025, Natera completed the acquisition of Foresight Diagnostics, which included a developed technology intangible asset valued at $335.3 million. The upfront cost for this acquisition was $275 million, with potential earnouts of an additional $175 million.

Capital Expenditures

• Net cash used in investing activities for the full year 2025 was $155.2 million.
• Natera's research and development costs for 2025 reached $1,801.4 million, a 44.6% increase from 2024, reflecting significant investment in new product offerings and enhancements.
• For 2026, research and development costs are projected to range from $750 million to $850 million, with a continued focus on innovation and expanding into new indications.